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Volume of interest delineation techniques
for 18F-FDG PET-CT scans during
neoadjuvant extremity soft tissue sarcoma
treatment in adults: a feasibility study
Marc G. Stevenson1, Lukas B. Been1, Harald J. Hoekstra1, Albert J. H. Suurmeijer2, Ronald Boellaard3,4
and Adrienne H. Brouwers3*
Abstract
Background: This study explores various volume of interest (VOI) delineation techniques for fluorine-18-fluorodeoxyglucose
positron emission tomography with computed tomography (18F-FDG PET-CT) scans during neoadjuvant extremity soft
tissue sarcoma (ESTS) treatment.
Results: During neoadjuvant treatment, hyperthermic isolated limb perfusion (HILP) and preoperative external beam
radiotherapy (EBRT), 11 patients underwent three 18F-FDG PET-CT scans. The first scan was made prior to the HILP,
the second after the HILP but prior to the start of the EBRT, and the third prior to surgical resection. An automatically
drawn VOIauto, a manually drawn VOIman, and two gradient-based semi-automatically drawn VOIs (VOIgrad and VOIgrad+)
were obtained. Maximum standardized uptake value (SUVmax), SUVpeak, SUVmean, metabolically active tumor volume
(MATV), and total lesion glycolysis (TLG) were calculated from each VOI. The correlation and level of agreement
between VOI delineation techniques was explored. Lastly, the changes in metabolic tumor activity were related to the
histopathologic response. The strongest correlation and an acceptable level of agreement was found between the
VOIman and the VOIgrad+ delineation techniques. A decline (VOIman) in SUVmax, SUVpeak, SUVmean, TLG, and
MATV (all p < 0.05) was found between the three scans. A > 75% decline in TLG between scan 1 and scan 3
possibly identifies histopathologic response.
Conclusions: The VOIgrad+ delineation technique was identified as most reliable considering reproducibility when
compared with the other VOI delineation techniques during the multimodality neoadjuvant treatment of locally
advanced ESTS. A significant decline in metabolic tumor activity during the treatment was found. TLG deserves
further exploration as predictor for histopathologic response after multimodality ESTS treatment.
Keywords: Soft tissue sarcoma, 18F-FDG PET-CT, Limb perfusion, Preoperative radiotherapy
Background
Soft tissue sarcomas (STS) are relatively rare malignan-
cies, accounting for less than 1% of all cancers in adults.
The number of patients presenting with STS each year is
600–700 in the Netherlands, leading to approximately
300 STS related deaths annually [1, 2].
Roughly 50–60% of the STS arise in the extremities
[3, 4]. At presentation, some of these extremity soft tis-
sue sarcomas (ESTS) are considered non-resectable or
“locally advanced.” Since the 1990s, neoadjuvant hyper-
thermic isolated limb perfusion (HILP) has been used
in Europe to prevent limb amputation in these patients
[5], resulting in a limb salvage rate of 80–90% in locally
advanced ESTS nowadays [6–9]. HILP is used in all
types of adult locally advanced ESTS. It allows to ad-
minister regional chemotherapy in high doses, as the
affected limb is isolated from the systemic circulation
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during the procedure. Neoadjuvant systemic chemo-
therapy in ESTS is currently under ongoing investigation,
as the data available considering patients’ oncological out-
come are inconsistent [10–12].
Fluorine-18-fluorodeoxyglucose positron emission
tomography with computed tomography (18F-FDG
PET-CT) scans have been used to evaluate tumor
changes following HILP in locally advanced ESTS since
the mid-1990s [13]. Pretreatment maximum standard-
ized uptake value (SUVmax), metabolically active tumor
volume (MATV), and total lesion glycolysis (TLG) were
identified as significant predictors for overall survival in
STS in a recent meta-analysis [14]. Furthermore,
post-treatment SUVmax was shown to be promising in
monitoring treatment response. However, the identifi-
cation of this latter parameter was solely based on two
articles included in this meta-analysis. The first only in-
cluded rhabdomyosarcomas, which is a chemosensitive
sarcoma, and the second only included chest wall sarcomas
[14–16].
The SUVmax of a lesion depends solely on the highest
measured 18F-FDG uptake in one voxel, thereby making
the measured SUVmax susceptible for noise [17]. Fur-
thermore, the question remains whether this one meas-
urement is representative for large, heterogeneous
tumors, as STS. In contrast, the SUVmax is the most ro-
bust parameter when comparing various software delin-
eation programs, delineation methods, and observers
[18]. The outcome of MATV and TLG parameters are
much more dependent of the method of tumor delinea-
tion and the software program used for these analyses.
We hypothesized that the use of peak standardized up-
take value (SUVpeak) and mean standardized uptake
value (SUVmean) in addition to SUVmax, TLG, and
MATV might result in a more reliable prediction of
tumor changes induced by neoadjuvant treatment.
To the best of our knowledge, the use of various
VOI delineation techniques has not yet been explored
in and during the neoadjuvant treatment of STS. Fur-
thermore, in this patient population, no sequential
analysis of multiple 18F-FDG PET-CT scans has been
performed previously. In this feasibility study, con-
secutive 18F-FDG PET-CT scans per patient were used
to investigate the use of four VOI delineation tech-
niques because variations in VOI will directly affect
the measured SUVmean, MATV, and TLG and could
thus affect the performance of the PET assessments.
Furthermore, we explored the changes in metabolic
tumor activity (SUVmax, SUVpeak, SUVmean, MATV,
and TLG) to neoadjuvant HILP and preoperative
EBRT during the treatment course of locally advanced
ESTS. Lastly, the relationship between changes in
metabolic tumor activity and histopathologic response
was explored.
Methods
This study has been approved by the Institutional
Review Board (IRB), and the need for written informed
consent was waived (IRB case number 2016.984). From
2011 to 2017, 11 patients with a median age of 64 (IQR
44–74; range 32–74) years were treated according to a
novel treatment regimen consisting of neoadjuvant HILP,
preoperative hypofractionated EBRT, followed by surgi-
cal resection of the tumor. All patients were diagnosed
with a locally advanced, non-metastatic, high-grade
ESTS (Table 1). Patients eligible for HILP treatment
were included in this novel treatment regimen based
on a tumor board decision. Inclusion and exclusion cri-
teria, as well as treatment details, have been described
in more detail elsewhere [19]. Patients were scheduled
for three 18F-FDG PET-CT scans. The first scan was
made prior to the start of neoadjuvant treatment (base-
line) and the second after the HILP, but prior to the
start of the preoperative EBRT and was additionally
used for EBRT delineation. The third scan was made
after completion of the neoadjuvant treatment (HILP
Table 1 Patient and tumor characteristics
Patient number Gender Age (years) Histopathologic findings Tumor location Tumor size (cm)
1 M 32 Synovial sarcoma Upper leg 6
2 F 41 Synovial sarcoma Lower leg 4
3 F 74 Pleomorphic undifferentiated sarcoma Upper leg 10
4 M 54 Pleomorphic undifferentiated sarcoma Upper leg 17
5 M 63 Pleomorphic undifferentiated sarcoma Lower leg 9
6 M 71 Myxofibrosarcoma Upper leg 5
7 M 44 Myxofibrosarcoma Upper leg 17
8 M 74 Pleomorphic undifferentiated sarcoma Knee 7
9 M 64 Leiomyosarcoma Knee 6
10 M 75 Pleomorphic undifferentiated sarcoma Lower leg 8
11 M 67 Leiomyosarcoma Knee 6
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and EBRT), but prior to surgical resection. Figure 1
illustrates the change in 18F-FDG uptake during the
treatment course for one of the patients.
18F-FDG PET-CT
The 18F-FDG PET-CT scans were performed using a
hybrid PET-CT scanner (Siemens Biograph mCT). Pa-
tients fasted at least 6 h prior to scanning, and fasting
glucose levels were checked at time of injection; none
of the patients suffered from diabetes mellitus. 18F-FDG
(3 MBq/kg) was injected, and the PET-CT scan was
started 1 h afterwards. Patients were scanned in supine
position, and images of the affected limb were acquired
in 3D mode, in two to five bed positions, 1–3 min/bed
position based on the patient’s body weight. A preceding
low dose CT scan was performed and used for attenuation
and scatter correction. All images were reconstructed
using an EARL compliant protocol; from 2011 to 2014,
the images were reconstructed using the following recon-
struction: 3i_24s, image size 400, filter Gaussian, and
FWHM 5.0 mm, and from 2014 to 2017, the images were
reconstructed with the following reconstruction parame-
ters: 3i_21s, image size 256, filter Gaussian, FWHM
6.5 mm, and quality ref. mAS 30. All scans were acquired
according to European Association of Nuclear Medicine
guidelines (version 1.0/2.0) [20, 21].
Image analyses
Scans were imported into Accurate (in-house developed
analysis software, as previously used by Frings and Kra-
mer et al. [22, 23]) and recently described by Boellaard
[24]. Scans were reviewed and analyzed by one re-
searcher. To explore the effect of various delineation
techniques on the measurement of the metabolic pa-
rameters, the volume of interest (VOI) of each tumor
was drawn in four different ways: (1) an automatically
drawn VOIauto (using 50% of the SUVpeak contour, cor-
rected for local background [22]), (2) a manually drawn
VOIman (visually following tumor contours), and (3) a
semi-automatic drawn VOIgrad (a contour that is lo-
cated at the maximum PET image intensity gradient
near the boundary of the tumor). Because of tumor het-
erogeneity, necrotic tumor parts (mostly tumor centers)
were not included in this third VOI. Therefore, a fourth
VOI was derived from the VOIgrad, in which all necrotic
tumor parts were manually filled and included, result-
ing in the fourth VOIgrad+ (Fig. 2).
Five metabolic parameters, SUVmax (voxel with the
highest SUV value), SUVpeak (using a 1 mL sphere),
SUVmean, TLG (SUVmean ×MATV), and MATV, all
based on lean body mass, as recommended by Boellaard
et al. [21], were derived for the four VOI delineation
techniques.
Due to tumor necrosis in most tumors, either
treatment-induced or due to tumor heterogeneity, only
the VOIman comprised the entire tumor (including ne-
crosis). Therefore, the VOIman was chosen as reference
measurement, and the other VOI techniques were com-
pared with the VOIman. We selected VOIman as reference
VOI for pragmatic reasons (as the VOIman encompasses
the entire tumor), not suggesting that this approach
is best.
Correlation analyses, Bland-Altman analyses, and pa-
tient ranking were performed to compare correlation
and level of agreement between the VOI delineation
techniques. Bland-Altman analyses [25] and patient
ranking are described in more detail in Additional file 1.
Changes in metabolic tumor activity during neoadjuvant
treatment were measured using the five metabolic pa-
rameters obtained from the reference VOIman and were
related to histopathologic responses. Histopathologic
tumor responses were established in accordance with
the European Organization for Research and Treatment
of Cancer-Soft Tissue and Bone Sarcoma Group
(EORTC-STBSG) STS response score [19]. Grade A rep-
resents no stainable tumor cells, grade B single stainable
Fig. 1 18F-FDG uptake throughout the tumor for one of the patients during the treatment course. Coronal 18F-FDG PET-CT images showing the
heterogeneous 18F-FDG uptake throughout the tumor for one of the patients during the treatment course. a Scan 1 (baseline). b Scan 2 (after HILP).
c Scan 3 (after EBRT)
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tumor cells or small clusters (overall below 1% of the
whole specimen), grade C ≥ 1 to < 10% stainable tumor
cells, grade D ≥ 10 to < 50% stainable tumor cells, and
grade E ≥ 50% stainable tumor cells [26].
Histopathologic responders had tumor remnants
which showed < 10% stainable cells, combining response
grades A, B, and C. Non-responders had ≥ 10% stainable
cells in their tumor remnant, grade D or E. Lastly, the
relationship between changes in metabolic tumor activity
and histopathologic responses was explored.
Statistical analysis
Discrete variables were summarized with frequencies
and percentages and continuous variables with me-
dians and interquartile ranges (IQRs); none of the
variables were normally distributed. Fisher’s exact and
Mann-Whitney U test were used to compare vari-
ables. Wilcoxon signed rank and Friedman’s test were
used to compare the measurements between the three
scans. Correlation coefficients were calculated and
tested using Spearman’s test. The level of agreement
between VOI techniques was determined by
Bland-Altman analyses [25]. A p value < 0.05 indi-
cated statistical significance. Microsoft Excel (2010)
was used to create the Bland-Altman plots. SPSS ver-
sion 23.0 (IBM SPSS Statistics for Windows, Version
23.0 Armonk, NY: IBM Corp) and GraphPad Prism
version 5.04 (GraphPad Software for Windows, San
Diego California USA) were used for statistical
analyses.
Results
Thirty-two 18F-FDG PET-CT scans were acquired. The
third PET-CT scan of patient 10 could not be performed
due to scheduling difficulties. For patient 1, in scan 3 it
was not possible to draw a VOIauto, since the tumor
showed an almost complete metabolic response at this
treatment stage and it did not meet the margin thresh-
olds to complete the VOIauto. Since it was possible to de-
fine the other three types of VOIs, this scan was
included in the analyses and a value of zero was given to
the metabolic parameters for the VOIauto. The median
time between the HILP and scan 2 was 21 [18–21] days,
whereas the time between the end of EBRT and scan 3
was 3 (1–3) days.
Correlation, level of agreement, and ranking of patients
between VOIs
The correlation between VOIs for all scans and all meta-
bolic parameters was strongest between the VOIman and
the VOIgrad+, as indicated in gray in Table 2. The
Bland-Altman plots showed an acceptable level of
agreement between the VOIman and the VOIgrad+
(Additional file 2: Figure S1).
No larger difference than 1 place in ranking for
SUVmean, and TLG for the serial
18F-FDG PET-CT
scans was found when comparing the VOIman and the
VOIgrad+ delineation techniques, for the MATV no
larger difference than 2 places in ranking was found.
A relative large difference of 4 or more in ranking
between VOI delineation techniques is indicated in
gray in Additional file 3: Table S1. Among others, this
was found for the MATV at scan 1 of patient 7 with con-
siderable necrotic tumor parts. The measured MATV was
found to be highest when using the VOIman, grad and grad+
techniques. However, when the VOIauto technique was
used, it was only ranked a 9th place due to exclusion of
tumor necrosis.
Fig. 2 Differences in tumor delineation between the four VOI delineation techniques. An example illustrating the differences in tumor delineation
between the four VOI delineation techniques, for patient 4 scan 2. a VOIauto. b VOIman. c VOIgrad. d VOIgrad+
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Metabolic tumor activity
During neoadjuvant treatment, all five metabolic param-
eters for the reference VOIman declined between scans 1
and 3 (all p < 0.05, Fig. 3, Table 3).
This decline was further explored by calculating the
absolute and the percentage difference between the
three serial scans. The percentage difference was ob-
tained by dividing the difference between scans by the
measured value of the first scan. A significant decline
in SUVmax, SUVpeak, and SUVmean was found between
scan 1 vs. scan 2, as well as between scan 1 vs. scan
3. However, no significant decline in SUVmax, SUV-
peak, and SUVmean was found between scan 2 vs. scan
3. The decline in TLG was significant between all ser-
ial scans. A significant decline in MATV was found be-
tween scan 2 vs. scan 3. The decline in metabolic
tumor activity for all parameters except MATV was lar-
gest between scan 1 vs. 2, whereas the decline in
MATV was largest between scan 2 vs. 3 (Fig. 4,
Table 4).
Histopathologic response
Histopathologic response to neoadjuvant treatment varied
among the 11 patients, as follows: one grade A (9.1%), one
grade B (9.1%), two grade C (18.2%) (totaling to four histo-
pathologic responders (36.4%)), five grade D (45.5%), and
two grade E (18.2%) (totaling to 7 non-responders
(64.4%)). The histopathologic responders seem to be iden-
tifiable by a decline in TLG of > 75% between scans 1 and
3 calculated using the VOIman (Table 5).
To further explore the identification of the histo-
pathologic responders, the difference and percentage
difference in TLG between scans 1 and 3 for the four VOI
delineation techniques was calculated (Additional file 4:
Table S2). A calculated decline in TLG of > 75% using the
VOIgrad/grad+ identified the same histopathologic re-
sponders as the VOIman. The VOIauto however failed to
identify patient 5 as histopathologic responder. Further-
more, a > 75% decline in TLG was also found with the
VOIauto and VOIgrad in patients 3 and 4 and with the
VOIgrad+ in patient 4.
Table 2 Spearman’s correlation between the VOIman and VOIauto/grad/grad+ for the serial
18F-FDG PET-CT scans
Parameter Scan 1 Scan 2 Scan 3
Correlation coefficient p value Correlation coefficient p value Correlation coefficient p value
SUVmax
VOIman-auto 1.000 NA 1.000 NA 0.988 < 0.001
VOIman-grad 1.000 NA 1.000 NA 1.000 NA
VOIman-grad+ 1.000 NA 1.000 NA 1.000 NA
SUVpeak
VOIman-auto 1.000 NA 1.000 NA 0.988 < 0.001
VOIman-grad 1.000 NA 1.000 NA 1.000 NA
VOIman-grad+ 1.000 NA 1.000 NA 1.000 NA
SUVmean
VOIman-auto 0.964 < 0.001 0.836 0.001 0.564 0.090
VOIman-grad 0.991 < 0.001 0.882 < 0.001 0.758 0.011
VOIman-grad+ 0.991 < 0.001 0.982 < 0.001 0.988 < 0.001
TLG
VOIman-auto 0.845 0.001 0.982 < 0.001 0.842 0.002
VOIman-grad 0.991 < 0.001 1.000 NA 0.976 < 0.001
VOIman-grad+ 0.991 < 0.001 0.991 < 0.001 0.988 < 0.001
MATV
VOIman-auto 0.309 0.355 0.555 0.077 0.430 0.214
VOIman-grad 0.955 < 0.001 0.973 < 0.001 0.806 0.005
VOIman-grad+ 0.936 < 0.001 1.000 NA 0.964 < 0.001
Spearman’s test for correlations was used to calculate significance. The strongest correlation for the three PET scans was found between the VOIman and the
VOIgrad+, as indicated in gray
VOI volume of interest, VOIman manually drawn VOI, VOIauto automatically drawn VOI, VOIgrad VOI based on the gradient between voxels, VOIgrad+ VOIgrad + necrosis,
18F-FDG PET-CT fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography, SUVmax maximum standardized uptake value, SUVpeak peak
standardized uptake value, SUVmean mean standardized uptake value, TLG total lesion glycolysis, MATV metabolically active tumor volume,
IQR interquartile range, NA not applicable







































































































Fig. 3 Course in metabolic tumor activity (VOIman) during neoadjuvant treatment for each patient individually. The course in metabolic tumor activity
for the VOIman during the neoadjuvant treatment for each patient individually for the serial
18F-FDG PET-CT scans. a SUVmax. b SUVmean. c SUVpeak.
d Metabolically active tumor-volume (MATV). e Total lesion glycolysis (TLG)
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Discussion
This study studying four VOI delineation techniques in
three consecutive 18F-FDG PET-CT scans per patient
demonstrates a significant decline in metabolic tumor
activity (VOIman) during the neoadjuvant treatment,
consisting of HILP and preoperative EBRT, of locally ad-
vanced ESTS. The decline in SUVmax, SUVpeak, SUVmean,
and TLG between scan 1 vs. 2 implies that the HILP
accounts for the largest effect on metabolic tumor ac-
tivity. The MATV seems to be affected most by the
EBRT, given the significant decline found between
scan 2 vs. 3.
In search of a uniform and reproducible way to calcu-
late changes in metabolic tumor activity in these upfront
highly heterogeneous tumors, the use of four different
VOI delineation techniques was studied. The VOIman
(defined as reference VOI) is the only delineation tech-
nique in which the entire tumor is encompassed inde-
pendently of the amount of necrosis present in the
tumor. Therefore, the VOIman delineation technique
seems to be most reliable when used for calculating the
metabolic tumor activity. However, the VOIman delinea-
tion technique is time-consuming, making it unfit for
implementation into daily practice. A high correlation,
acceptable level of agreement, and comparable ranking
was found between the VOIman and the VOIgrad+ delin-
eation techniques. The differences in ranking between
the four VOI delineation techniques are best explained
by the high amount of necrosis present in these tumors,
as tumor necrosis did not meet the margin thresholds of
the VOIauto and VOIgrad. To obtain the VOIgrad+, the ne-
crosis was manually included, and therefore, the ranking
of patients was comparable to the ranking according to
the VOIman.
Thus, the VOIgrad+ delineation technique seems to be
a reliable and reproducible technique for the delineation
of heterogeneous tumors as ESTS. Further studies in-
cluding larger patient cohorts in various solid tumor
types are necessary for the validation and reproducibility
of the various VOI delineation techniques. This study,
however, demonstrates that the applied VOI delinea-
tion technique is important to consider because we
found that assessment of response based on metabolic
parameters derived from different VOIs may differ
across subjects.
The metabolic tumor changes during neoadjuvant
treatment between scan 1 vs. scan 3 were analyzed and
compared with the corresponding histopathologic tumor
response. Out of the five metabolic parameters tested,
TLG seemed to identify the histopathologic responders
most reliably (> 75% decrease in TLG between scan 1
and scan 3) when using the VOIman delineation tech-
nique. Using the 75% decrease in TLG as a cutoff value
was derived empirically from the data, used as example,
and to obtain pilot data for using and comparing these
techniques. When compared with the VOIman delinea-
tion technique, the VOIgrad+ technique identified the
same histopathologic responders with only one add-
itional patient. It seems that these two delineation tech-
niques most reliably identify histopathologic responders,
because they include tumor necrosis. The difference in
performance of the VOIman and VOIgrad+ delineation
techniques in identifying histopathologic responders is
very subtle. However, the VOIgrad+ delineation technique
was found to be easier in use and is considerably less
time-consuming than the VOIman technique, making it
more suitable for implementation into daily practice.
The VOI delineation techniques and the TLG cutoff
value need confirmation in larger patient cohorts.
During the last years, the predictive value of 18F-FDG
PET-CT scans in staging and monitoring treatment re-
sponse during neoadjuvant treatment has been established
for various solid tumors (including metastatic colorectal
cancer and non-small cell lung cancer [23, 27–29]. There-
fore, further ESTS studies in which metabolic tumor
activity, e.g., > 75% decrease in TLG with VOIman and/
or VOIgrad+, is explored as predictor for monitoring
therapy response, for histopathologic findings, and for
oncological outcome are warranted. The identification
of reproducible and reliable VOI delineation tech-
niques, as well as the identification of robust PET pa-
rameters for the interpretation of changes in metabolic
tumor activity, is relevant because this will enable clini-
cians to shorten delineation time and to compare
Table 3 Metabolic tumor activity for the VOIman for the serial
18F-FDG PET-CT scans
Parameter Scan 1 Scan 2 Scan 3 p value
SUVmax 6.5 (3.3–9.5) 2.8 (2.4–4.1) 2.7 (1.9–3.6) 0.002
SUVpeak 5.6 (2.8–8.5) 2.5 (1.9–3.4) 2.4 (1.6–3.0) 0.001
SUVmean 2.4 (1.7–3.7) 1.3 (1.0–2.0) 1.2 (1.0–1.7) 0.006
TLG 434.8 (108.6–1112.8) 159.9 (44.7–570.9) 137.5 (22.6–572.6) 0.003
MATV (ml) 124.4 (64.8–474.2) 98.3 (35.2–534.2) 87.1 (15.1–437.7) 0.025
Data presented as median (IQR)
VOI volume of interest, VOIman manually drawn VOI,
18F-FDG PET-CT fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography,
SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, TLG total lesion glycolysis,
MATV metabolically active tumor volume, IQR interquartile range
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results between observers, patients, and centers for
ESTS and for other solid tumor types.
This study has some limitations, such as the retro-
spective character and the small patient population of
the study. Only 11 patients were included; however, all
patients but one underwent all three 18F-FDG PET-CT
scans, and therefore, it was possible to establish the
changes in metabolic tumor activity during the neoadju-
vant treatment in all patients. Possibly, the interpretation



















































































































Fig. 4 Changes in metabolic tumor activity (VOIman) during neoadjuvant treatment for the serial
18F-FDG PET-CT scans. Changes in metabolic
tumor activity for the VOIman during the neoadjuvant treatment for the serial
18F-FDG PET-CT scans. Median and interquartile ranges are indicated.
a SUVmax. b SUVmean. c SUVpeak. d Metabolically active tumor volume (MATV). e Total lesion glycolysis (TLG). *p < 0.05;
#p < 0.01
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changes following the EBRT. These inflammatory
changes might partly explain the significantly more pro-
nounced decrease in metabolic tumor activity following
the HILP then following the EBRT, as found in the current
series. Despite this potential bias due to radiation-induced
local inflammatory changes, a decrease in metabolic
tumor activity between scans 1 and 3 was found, which
theoretically might have been larger without these
changes. For the purpose of this study, all data considering
the metabolic tumor activity were obtained from an add-
itional analyses of the 18F-FDG PET-CT scans, since these
data are not used in routine patient care. Interestingly, the
EORTC-STBSG response score [26] could be used to ex-
plore the relationship between changes in metabolic
tumor activity and histopathologic response. However, the
prognostic value of the STS response score according to
the proportion of stainable tumor cells needs further
validation [30].
Conclusions
This study identified the VOIgrad+ delineation tech-
nique as most reliable considering reproducibility
when compared with the other delineation techniques
during the multimodality neoadjuvant treatment of lo-
cally advanced ESTS. Moreover, the VOIgrad+ delineation
technique was considerably less time-consuming to per-
form when compared to the VOIman technique, potentially
resulting in easier implementation in clinical practice. A
significant decline in metabolic tumor activity during the
treatment was found. The decrease in metabolic tumor
Table 4 Changes in metabolic tumor activity for the VOIman during the neoadjuvant treatment between the serial
18F-FDG PET-CT scans
Parameter Scan 1 vs. 2 Scan 2 vs. 3 Scan 1 vs. 3
Δ Δ % Δ Δ % Δ Δ %
SUVmax − 2.6 (− 6.4 to − 0.5)
# − 37.7 (− 67.7 to − 16.4) − 0.3 (− 0.5 to − 0.1) − 13.6 (− 17.5 to − 4.7) − 3.2 (− 6.7 to − 0.5)# − 41.6 (− 73.5 to − 27.7)
SUVpeak −2.8 (− 5.6 to − 0.4)
# − 45.8 (− 67.4 to − 17.3) − 0.2 (− 0.5 to 0.0) − 9.3 (− 16.8 to 0.4) − 2.9 (− 5.9 to − 0.3)# − 45.1 (− 74.4 to − 21.9)
SUVmean − 0.9 (− 1.9 to − 0.1)
# − 39.3 (− 52.0 to − 13.2) − 0.1 (− 0.2 to 0.0) − 4.6 (− 17.2 to 2.3) − 1.0 (− 2.3 to − 0.2)# − 44.1 (− 57.2 to − 17.0)
TLG − 233.6 (− 637.9 to − 28.0)* − 52.6 (− 73.6 to − 36.3) − 18.4 (− 57.0 to − 10.6)# − 16.3 (− 59.7 to − 5.5) − 285.0 (− 714.7 to − 34.4)* − 67.5 (− 82.6 to − 38.2)
MATV (ml) − 22.1 (− 48.2 to 33.5) − 7.5 (− 44.9 to 23.5) − 13.2 (− 53.0 to − 5.3)# − 19.8 (− 49.4 to − 2.7) − 25.4 (− 70.6 to 27.6) − 31.2 (− 67.2 to 3.8)
Data presented as median (IQR)
VOI volume of interest, VOIman manually drawn VOI,
18F-FDG PET-CT fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography,
SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, TLG total lesion glycolysis, MATV
metabolically active tumor volume, IQR interquartile range. *p < 0.05; #p < 0.01
Table 5 Changes in metabolic tumor activity for the VOIman during the neoadjuvant treatment between
18F-FDG PET-CT scans 1
and 3, combined with the corresponding histopathologic tumor response for each patient
Patient
number
Scan 1 vs. 3 SUVmax Scan 1 vs. 3 SUVpeak Scan 1 vs. 3 SUVmean Scan 1 vs. 3 TLG Scan 1 vs. 3 MATV (ml) EORTC-STBSG
response grade [26]
Δ Δ % Δ Δ % Δ Δ % Δ Δ % Δ Δ %
1 − 0.5 − 32.0 − 0.4 − 27.0 − 0.2 − 22.4 − 44.4 − 79.2 − 38.0 − 73.1 C
2 0.1 5.2 − 0.0 − 1.7 0.0 − 0.7 − 4.4 − 36.3 − 6.4 − 35.8 D
3 − 2.0 − 36.6 − 2.0 − 40.7 − 1.3 − 54.6 − 578.1 − 51.9 27.9 5.9 D
4 − 4.8 − 32.7 − 4.9 − 37.6 − 3.1 − 65.1 − 1986.4 − 74.3 − 150.4 − 26.5 D
5 − 6.6 − 75.0 − 5.7 − 76.2 − 1.2 − 47.6 − 165.7 − 81.8 − 54.4 − 65.2 A
6 − 0.5 − 15.0 − 0.2 − 6.4 0.1 5.0 53.8 49.5 27.5 42.4 E
7 − 3.2 − 59.0 − 2.5 − 56.5 − 0.7 − 40.6 − 883.9 − 38.8 38.6 3.1 D
8 − 18.2 − 83.8 − 17.3 − 87.3 − 5.2 − 83.7 − 658.4 − 85.4 − 12.8 − 10.3 B
9 − 3.2 − 46.5 − 3.2 − 49.5 − 0.8 − 25.5 − 278.7 − 60.7 − 73.5 − 47.3 D
10 NA NA NA NA NA NA NA NA NA NA E
11 − 7.0 − 73.1 − 6.3 − 73.8 − 2.0 − 54.4 − 291.3 − 91.7 − 69.6 − 81.9 C
Histopathologic responders are indicated in gray. A percentage difference of > 75% in TLG seemed to identify the histopathologic responders; these values
were encircled
18F-FDG PET-CT fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography, SUVmax maximum standardized uptake value,
SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, TLG total lesion glycolysis, MATV metabolically active tumor volume,
EORTC-STBSG European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group
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activity was significantly more pronounced after HILP
than after preoperative radiotherapy. TLG seems promis-
ing, but warrants further confirmation, as predictor for
histopathologic response in ESTS. Further studies in lar-
ger ESTS patient cohorts in which the investigated meta-
bolic parameters and VOI delineation techniques are
confirmed and validated as predictors for monitoring
treatment response, for histopathologic response, and
for oncological outcome are warranted, as this will re-
sult in an increase in the clinical applicability of
metabolic tumor activity assessments in longitudinal
sarcoma 18F-FDG PET-CT studies.
Additional files
Additional file 1: Supplemental Methods. (DOCX 17 kb)
Additional file 2: Figure S1. Bland-Altman plots showing the level of
agreement between the VOIman and the VOIauto/grad/grad+ for the serial
18F-FDG PET-CT scans for A SUVmean, B total lesion glycolysis (TLG), and C
metabolically active tumor-volume (MATV). (PDF 529 kb)
Additional file 3: Table S1. Ranking of patients for SUVmean, TLG, and
MATV according to the four VOI delineation techniques. (DOCX 26 kb)
Additional file 4: Table S2. Changes in TLG according to the four VOI
delineation techniques between 18F-FDG PET-CT scan 1 and scan 3,
combined with the corresponding histopathologic tumor response for
each patient. (DOCX 22 kb)
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